Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Esperion Theraptc (NQ: ESPR )

2.470 +0.060 (+2.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Esperion Theraptc

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Nasdaq Rises 50 Points; US Factory Orders Down 1.6% In January
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 33,471.14 while the NASDAQ rose... 
Via Benzinga
Esperion Therapeutics Stock Is Diving: What's Going On?
Esperion Therapeutics Inc (NASDAQ: ESPR) shares are trading lower Monday after the company published new data on its treatment aimed at  
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Gainers Secoo Holding Limited (NASDAQ: SECO) rose 44% to $1.44 in pre-market trading after dipping over 31% on Friday. 
Via Benzinga
The Latest Analyst Ratings for Esperion Therapeutics
Via Benzinga
Looking Into Esperion Therapeutics's Return On Capital Employed
Via Benzinga
Esperion Therapeutics's Earnings Outlook
Via Benzinga
Esperion Long Term Data On Cholesterol Medication's Ability To Cut Cardiovascular Risk Fails To Impress Investors
Via Benzinga
Esperion Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Launches New Scientific Website
Designed Specifically for the Scientific and Medical Communities, esperionscience.com Features Information about Esperion’s Landmark CLEAR Outcomes Study, Company Pipeline and More 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in the Cowen 43rd Annual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
CLEAR Outcomes Company Update Call: Detailed Results Discussion
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC
– NEXLETOL® (bempedoic acid) is the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint – 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
Via Benzinga
RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
NASCAR Champion Brad Keselowski to Run No. 6 NEXLIZET (bempedoic acid and ezetimibe) Ford in Famed Daytona 500 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Top Picks For 2023: Esperion
Esperion is a de-risked biotech company in the cardiovascular sector with its lead drug, bempedoic acid, already FDA approved to reduce LDL cholesterol. Let's take a closer look at why it's a top pick... 
Via Talk Markets
CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in January Investor Meetings
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Therapeutics Reports Sooner Than Expected Positive Data From Nexletol Trial
Via Benzinga
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Appoints Ben Halladay Chief Financial Officer
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Therapeutics's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q3, Esperion Therapeutics's (NASDAQ:ESPR) reported sales totaled $18.98 million. Despite a 16.9% increase in earnings, the company posted a loss of $55.12... 
Via Benzinga
Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Jefferies London Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.